1. Medicines
  2. Ophthalmology
  3. LUCENTIS® (ranibizumab)
  4. Resources
  5. Resources for HCPs
  6. Wolverhampton Eye Infirmary audit data

Prescribing information

 

Wolverhampton Eye Infirmary audit data

Mr Ajay Bhatnagar discusses his experience of using anti-VEGF injections for treating DMO at Wolverhampton Eye Infirmary. The audit covers all the patients who were treated over a period of 12 months.

 

Indications1

LUCENTIS 0.5 mg is indicated in adults for:

  • The treatment of neovascular (wet) age-related macular degeneration (AMD)
  • The treatment of visual impairment due to diabetic macular oedema (DMO)
  • The treatment of proliferative diabetic retinopathy (PDR)
  • The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)
  • The treatment of visual impairment due to choroidal neovascularisation (CNV).

LUCENTIS 0.2 mg is indicated in preterm infants for:

  • The treatment of retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 3+) or AP-ROP (aggressive posterior ROP) disease.

 

DMO, diabetic macular oedema; HCP, healthcare professional; VEGF, vascular endothelial growth factor; wAMD, wet age-related macular degeneration.

Reference

  1. LUCENTIS® (ranibizumab) Summary of Product Characteristics, July 2020.

     

LUC20-C030aa November 2020.
Ophthalmology
Resource
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]